Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
NCT07163611
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Membranous Nephropathy - PLA2R Induced
Interventions
DRUG:
Obinutuzumab administration
Sponsor
Radboud University Medical Center
Collaborators
[object Object]